- Home
- BERY vs IONS Comparison
BERY vs IONS Comparison
Compare BERY & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BERY
- IONS
- Stock Information
- Founded
- BERY 1967
- IONS 1989
- Country
- BERY United States
- IONS United States
- Employees
- BERY N/A
- IONS N/A
- Industry
- BERY Plastic Products
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- BERY Industrials
- IONS Health Care
- Exchange
- BERY Nasdaq
- IONS Nasdaq
- Market Cap
- BERY 7.2B
- IONS 6.0B
- IPO Year
- BERY 2012
- IONS 1991
- Fundamental
- Price
- BERY $68.49
- IONS $32.68
- Analyst Decision
- BERY Hold
- IONS Buy
- Analyst Count
- BERY 10
- IONS 18
- Target Price
- BERY $73.30
- IONS $62.00
- AVG Volume (30 Days)
- BERY 1.2M
- IONS 1.5M
- Earning Date
- BERY 02-05-2025
- IONS 02-19-2025
- Dividend Yield
- BERY 1.81%
- IONS N/A
- EPS Growth
- BERY N/A
- IONS N/A
- EPS
- BERY 4.38
- IONS N/A
- Revenue
- BERY $12,258,000,000.00
- IONS $803,067,000.00
- Revenue This Year
- BERY N/A
- IONS N/A
- Revenue Next Year
- BERY $1.63
- IONS $10.85
- P/E Ratio
- BERY $15.60
- IONS N/A
- Revenue Growth
- BERY N/A
- IONS 30.57
- 52 Week Low
- BERY $49.64
- IONS $31.40
- 52 Week High
- BERY $73.31
- IONS $52.49
- Technical
- Relative Strength Index (RSI)
- BERY 63.72
- IONS 40.58
- Support Level
- BERY $64.91
- IONS $31.40
- Resistance Level
- BERY $66.95
- IONS $35.37
- Average True Range (ATR)
- BERY 1.07
- IONS 1.31
- MACD
- BERY 0.45
- IONS -0.23
- Stochastic Oscillator
- BERY 96.42
- IONS 29.09
About BERY Berry Global Group Inc.
Berry global Group Inc is a leading global supplier of plastic packaging products mainly sold to consumer-oriented end markets. The four business segments are consumer packaging international, consumer packaging North America, engineered materials, and health, hygiene, and specialties. The company primarily uses plastic resin as its raw material, purchased from a variety of suppliers. The majority of revenue comes from consumer packaging international due to the acquisition of RPC, which expanded the geographical areas in which the company operates. The consumer packaging segment consists of closures and dispensing systems, pharmaceutical devices and packaging, bottles and canisters, polythene films, recycling, containers, and technical components.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.